Case report: abemaciclib-induced syndrome of inappropriate antidiuretic hormone (SIADH) without underlying kidney injury in a patient with early-stage estrogen receptor (ER)+ breast cancer

Neil Carleton; Julia Foldi; Julia Foldi

doi:10.3389/fmed.2023.1338566

Frontiers in Medicine (Jan 2024)

Case report: abemaciclib-induced syndrome of inappropriate antidiuretic hormone (SIADH) without underlying kidney injury in a patient with early-stage estrogen receptor (ER)+ breast cancer

Neil Carleton,
Julia Foldi,
Julia Foldi

Affiliations

Neil Carleton: Women’s Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, United States
Julia Foldi: Women’s Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, United States
Julia Foldi: Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States

DOI: https://doi.org/10.3389/fmed.2023.1338566
Journal volume & issue: Vol. 10

Abstract

Read online

The CDK4/6 inhibitor, abemaciclib, is now the standard of care adjuvant therapy for patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) tumors at high risk of recurrence. Real-world usage uncovers emerging side effects that may have been previously unreported in clinical trials. Here, we present the clinical course of a patient who developed a syndrome of inappropriate antidiuretic hormone (SIADH) without underlying kidney injury due to abemaciclib use.

Published in Frontiers in Medicine

ISSN: 2296-858X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Medicine (General)
Website: http://www.frontiersin.org/journals/medicine

About the journal

Abstract

Keywords